A second opportunity to come for anti-angiogenics in prostate cancer?

Similar to the previous experience combining the anti-angiogenic agent bevacizumab with docetaxel, the use of sunitinib and prednisone (as compared to placebo and prednisone) did not result in prolongation of overall survival in patients with metastatic castration resistant prostate cancer (mCRPC) who had failed one previous docetaxel-based regimen. However, both progression-free survival (PFS) and response rate were significantly improved. Possible explanations to these findings and strategies to optimize the clinical application of anti-angiogenics in prostate cancer are discussed.